Anesiva Forms Joint Venture With Wanbang Biological
This article was originally published in PharmAsia News
SHANGHAI - Anesiva entered into a joint venture Oct. 14 with Jiangsu Wanbang Biological Pharmaceutical Corp., a subsidiary of Shanghai Fosun Pharmaceuticals, to establish additional manufacturing capacity for the worldwide supply of its fast-acting topical local analgesia Zingo (lidocaine hydrochloride monohydrate)
You may also be interested in...
SHANGHAI - Denmark-based dermatology company LEO Pharma is opening a China facility in Shanghai to market its leading anti-psoriasis product Daivobet, the company announced Dec. 8
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).